PDCD1 and cancer: Consistent with its role in boosting the immune response, the SASP benefits cancer immunotherapies by improving the efficacy of the immune checkpoint blockade (ICB), such as by sensitizing programmed cell death protein 1 (PD‐1) inhibitors [49].